Use of psychotropic medication among adolescents with borderline personality disorder: a 6-year descriptive follow-up study
Nordic Journal of Psychiatry · 11.11.2026 · 1-9
DOI: 10.1080/08039488.2026.2749574 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nordic Journal of Psychiatry, online erschienen am 11.11.2026. Verfasst von Toke Ulv Lenskjold und 9 weiteren Autor:innen. Beteiligte Einrichtung: Mental Health Services, Region Zealand East, Denmark. Die Arbeit nennt 51 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Psychotropic medications are widely used in the treatment of borderline personality disorder (BPD), despite limited supporting evidence. Characterizing the use of psychotropic medications in adolescents with BPD is a prerequisite for understanding the underlying factors that contribute to prescribing patterns, as well as for critically evaluating the clinical indications for such treatments. To the best of our knowledge, this study is the first to longitudinally assess psychotropic medication use in a sample of adolescents with BPD or BPD features over a six-year period. METHODS: Medication data were obtained from 110 adolescents with BPD or BPD features from medical records at baseline and at follow-ups after one, two, and six years. Descriptive analyses were conducted to characterize prescription patterns over time. RESULTS: Over the six-year follow-up period, the proportion of participants prescribed psychotropic medication remained high, increasing from 47% at baseline to 77% at the six-year follow-up, and polypharmacy was prevalent. Sertraline and quetiapine were most frequently prescribed, with quetiapine often used as pro re nata (PRN) medication. CONCLUSIONS: Our results indicate that treatment with psychotropic medication for BPD is initiated during adolescence and sustained over time, with high prescription rates and polypharmacy. High levels of psychiatric comorbidity and variable courses of BPD may, among other factors, influence the observed prescribing patterns. Considering the limited evidence supporting their effectiveness, and the potential adverse effects, our findings emphasize the need for research into the factors driving the excessive use of psychotropic medications in BPD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mental Health Services, Region Zealand East, Denmark.
- Department of Psychology, University of Copenhagen, Denmark.
- Mental Health Services, Region Zealand West, Slagelse, Denmark.
- Department of Psychology, University of Southern Denmark, Odense, Denmark.
- Psychiatric Research Unit, Mental Health Services, Region Zealand, Denmark.
- Private Practice, Roskilde, Denmark.
Zitieren
APA
Lenskjold, T. U., Jørgensen, M. S., Bo, S., Storebø, O. J., Poulsen, S. B., Beck, E., Kongerslev, M. T., Hastrup, L. H., Maagensen, M., & Simonsen, E. (2026). Use of psychotropic medication among adolescents with borderline personality disorder: a 6-year descriptive follow-up study. Nordic Journal of Psychiatry, 1-9. https://doi.org/10.1080/08039488.2026.2749574
Vancouver
Lenskjold TU, Jørgensen MS, Bo S, Storebø OJ, Poulsen SB, Beck E, et al. Use of psychotropic medication among adolescents with borderline personality disorder: a 6-year descriptive follow-up study. Nordic Journal of Psychiatry. 2026:1-9. doi:10.1080/08039488.2026.2749574
BibTeX
@article{Lenskjold2026,
author = {Lenskjold, Toke Ulv and Jørgensen, Mie Sedoc and Bo, Sune and Storebø, Ole Jakob and Poulsen, Stig Bernt and Beck, Emma and Kongerslev, Mickey Toftkjær and Hastrup, Lene Halling and Maagensen, Michael and Simonsen, Erik},
title = {Use of psychotropic medication among adolescents with borderline personality disorder: a 6-year descriptive follow-up study},
journal = {Nordic Journal of Psychiatry},
year = {2026},
pages = {1--9},
doi = {10.1080/08039488.2026.2749574}
}
EUVIMED